There has been increasing interest in the association between cancer and cerebrovascular disease in recent years. The primary mechanism of stroke in cancer patients is said to be the cancer associated hypercoagulation, particularly in patients without vascular risk factors. This article focuses on a clinical study that compared enoxaparin and warfarin therapy for secondary prevention of cancer-associated stroke. Cancer-associated stroke has distinct characteristics such as multiple vascular infarcts and markedly elevated D-dimer levels, which is considered to be the bio-marker of cancer-associated stroke.
This is said to be caused by the paraneoplastic hypercoagulability. The management is the prevention of recurrent embolism by anticoagulants. Materials and Methods The authors analyzed data from July 2006 and December 2012. Patients were labeled to have cancer-associated stroke if they…
